Back to Journals » International Journal of Nanomedicine » Volume 12

Improved LFIAs for highly sensitive detection of BNP at point-of-care

Authors Gong Y, Hu J, Choi JR, You M, Zheng Y, Xu B, Wen T, Xu F

Received 27 February 2017

Accepted for publication 5 May 2017

Published 15 June 2017 Volume 2017:12 Pages 4455—4466

DOI https://doi.org/10.2147/IJN.S135735

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Linlin Sun


Yan Gong,1–3 Jie Hu,1,2 Jane Ru Choi,2 Minli You,1,2 Yamin Zheng,1,2 Bo Xu,4 Ting Wen,3 Feng Xu1,2

1The Key Laboratory of Biomedical Information Engineering of Ministry of Education, Department of Biomedical Engineering, School of Life Science and Technology, Xi’an Jiaotong University, 2Bioinspired Engineering and Biomechanics Center (BEBC), Xi’an Jiaotong University, 3Xi’an Diandi Biotech Company, 4School of Finance and Economics, Xi’an Jiaotong University, Xi’an, People’s Republic of China

Abstract: Heart failure (HF) has become a major cause of morbidity and mortality with a significant global economic burden. Although well-established clinical tests could provide early diagnosis, access to these tests is limited in developing countries, where a relatively higher incidence of HF is present. This has prompted an urgent need for developing a cost-effective, rapid and robust diagnostic tool for point-of-care (POC) detection of HF. Lateral flow immunoassay (LFIA) has found widespread applications in POC diagnostics. However, the low sensitivity of LFIA limits its ability to detect important HF biomarkers (e.g., brain natriuretic peptide [BNP]) that are normally present in low concentration in blood. To address this issue, we developed an improved LFIA by optimizing the gold nanoparticle (GNP)–antibody conjugate conditions (e.g., the conjugate pH and the amount of added antibody), the diameter of GNP and the concentration of antibody embedded on the test line and modifying the structure of test strip. Through these improvements, the proposed test strip enabled the detection of BNP down to 0.1 ng/mL within 10–15 min, presenting ~15-fold sensitivity enhancement over conventional lateral flow assay. We also successfully applied our LFIA in the analysis of BNP in human serum samples, highlighting its potential use for clinical assessment of HF. The developed LFIA for BNP could rapidly rule out HF with the naked eye, offering tremendous potential for POC test and personalized medicine.

Keywords: heart failure, biomarker, colorimetric assays, personalized medicine

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]